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Comparison of Anxiety Between Smokers and Nonsmokers with Acute
Myocardial Infarction
Abstract
Background: Increased anxiety correlates with increased complications after acute myocardial infarction.
Anxiety levels and use of anxiolytic agents have not been compared between smokers and nonsmokers
hospitalized because of acute myocardial infarction.
Objectives: To compare anxiety level, sociodemographic factors, and clinical variables between smokers
and nonsmokers hospitalized with acute myocardial infarction and to examine predictors of use of βblockers and anxiolytic agents among smokers and nonsmokers.
Methods: Secondary data analysis of a prospective multisite study on anxiety in 181 smokers and 351
nonsmokers with acute myocardial infarction. Anxiety was measured by using the State Trait Anxiety
Inventory and the anxiety subscale of the Basic Symptom Inventory within 72 hours of admission.
Results: Smokers reported higher anxiety levels than nonsmokers reported on both anxiety scales.
Female smokers reported the highest anxiety and peak pain levels of all, yet women were the least likely
to receive anxiolytic agents. Smoking status was not a predictor for anxiety level when sex, peak pain, use
of β-blockers in the hospital, and age were controlled for. However, smokers were twice as likely as
nonsmokers to receive an anxiolytic agent and 60% more likely to receive a &beta-blocker in the
emergency department, and smokers were 80% more likely than nonsmokers to receive an anxiolytic
agent during hospitalization when these variables were controlled.
Conclusions: Older female smokers are at risk for complications because they are older than their male
counterparts and less likely to receive &beta-blockers and antianxiety medications in the emergency
department.
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COMPARISON OF ANXIETY BETWEEN SMOKERS AND
NONSMOKERS WITH ACUTE MYOCARDIAL INFARCTION
By Sharon L. Sheahan, PhD, FNP, Mary K. Rayens, PhD, Kyungeh An, RN, PhD, Barbara Riegel, RN, DNSc, CS,
Sharon McKinley, RN, PhD, Lynn Doering, RN, DNSc, Bonnie J. Garvin, RN, PhD, and Debra K. Moser, RN, DNSc.
From the University of Kentucky College of Nursing, Lexington, Ky (SLS, MKR, DKM), Acupuncture and Meridian
Science Research Center, Kyung Hee University, Seoul, Korea (KA), University of Pennsylvania, Philadelphia,
Pa (BR), University of Technology, Sydney and Royal North Shore Hospital, Sydney, Australia (SM), University
of California, Los Angeles, Los Angeles, Calif (LD), and The Ohio State University, Columbus, Ohio (BJG).

• BACKGROUND Increased anxiety correlates with increased complications after acute myocardial
infarction. Anxiety levels and use of anxiolytic agents have not been compared between smokers and
nonsmokers hospitalized because of acute myocardial infarction.
• OBJECTIVES To compare anxiety level, sociodemographic factors, and clinical variables between
smokers and nonsmokers hospitalized with acute myocardial infarction and to examine predictors of use
of β-blockers and anxiolytic agents among smokers and nonsmokers.
• METHODS Secondary data analysis of a prospective multisite study on anxiety in 181 smokers and 351
nonsmokers with acute myocardial infarction. Anxiety was measured by using the State Trait Anxiety
Inventory and the anxiety subscale of the Basic Symptom Inventory within 72 hours of admission.
• RESULTS Smokers reported higher anxiety levels than nonsmokers reported on both anxiety scales.
Female smokers reported the highest anxiety and peak pain levels of all, yet women were the least likely
to receive anxiolytic agents. Smoking status was not a predictor for anxiety level when sex, peak pain,
use of β-blockers in the hospital, and age were controlled for. However, smokers were twice as likely as
nonsmokers to receive an anxiolytic agent and 60% more likely to receive a β-blocker in the emergency
department, and smokers were 80% more likely than nonsmokers to receive an anxiolytic agent during
hospitalization when these variables were controlled.
• CONCLUSIONS Older female smokers are at risk for complications because they are older than their
male counterparts and less likely to receive β-blockers and antianxiety medications in the emergency
department. (American Journal of Critical Care. 2006;15:617-625)

E

ach year, an estimated 700 000 persons in the
United States have their first acute myocardial
infarction (AMI) and about 500 000 have a
recurrent infarction.1 Tobacco use remains a major
risk factor in coronary heart disease, contributing to
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33.5% of deaths annually, and an estimated 35 000
nonsmokers die of coronary heart disease as a consequence of exposure to environmental tobacco smoke.2,3
The prevalence of coronary heart disease and AMI is
projected to increase by 2010, when 40 million Americans will be aged 65 years or older.1
No studies comparing anxiety levels between smokers and nonsmokers hospitalized for an AMI have
been reported. Because AMI is associated with a high
level of anxiety and many patients with AMI are
smokers, the primary purpose of this study was to
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compare anxiety levels between smokers and nonsmokers hospitalized for AMI. A secondary aim was to determine whether use of anxiolytic agents and β-blockers
differs between smokers and nonsmokers when anxiety
level, peak pain level, sex, and age are controlled.
Patients with an AMI usually experience high levels
of anxiety.4-8 Some level of anxiety is a normal response
when one is confronted with a sudden health event
such as an AMI. A sustained high anxiety level, however, is associated with detrimental health outcomes
and increased in-hospital complications, including
ventricular arrhythmias and death.5,9-11 A psychophysiological stress perspective was used to guide this
study because smoking increases arousal of the autonomic nervous system and smokers, as a group, tend
to be more anxious. However, in their review of the
psychophysiological assessments of stress, Katkin et
al12 emphasize that stress reactivity is highly individualistic. Some individuals respond to stressful situations with greater autonomic arousal (increased heart
rate and blood pressure) than do nonreactors, and the
tendency to react to stressful events seems to be a stable enduring “traitlike” characteristic. Researchers
hypothesize that this β-adrenergic hyperreactivity pattern is a critical factor in hypertension, which often
precedes AMI.

Smoking increases autonomic system
arousal; smokers tend to be more anxious.
Certain medications (eg, β-blockers and anxiolytic agents) are recommended treatment for AMI
patients. According to clinical guidelines of the American Heart Association, all AMI patients should receive
β-blockers during hospitalization and after discharge
from the hospital.1 Consequently, studies of anxiety
among AMI patients should include controls for the
administration of β-blockers because these medications have antianxiety properties along with the anxiolytic agents.
Results of studies on the link between smoking
behavior and anxiety are conflicting. Some researchers
have reported a link between smoking behavior and
anxiety states and disorders.13,14 Patton et al15 found
that a subpopulation of smokers is more anxious than
other smokers. Other investigators16-19 have shown that
nicotine can act as an anxiolytic agent and as an antidepressant. Smokers consistently attribute their smoking
to its ability to reduce subjective stress and anxiety.20-23
Kassel and Shiffman24 found that smoking reduced
618

anxiety only when paired with a distracting activity.
Recent studies13,25 link smoking more strongly with
panic disorder, a specific anxiety disorder. Smokers
with an AMI often have additional comorbid conditions
(eg, hypertension, lung disease) that increase their risks
for adverse health outcomes. An examination of the
relationships between anxiety level and smoking status
may provide additional clinical information about this
high-risk group.
The questions addressed by this study were as
follows:
• Do smokers report higher levels of anxiety than
their nonsmoking counterparts?
• Do smokers receive more antianxiety medications than nonsmokers during hospitalization?

Methods
Design

The data for this study are from a cross-sectional,
prospective, comparative multicenter study that investigated differences in anxiety and clinical outcomes
between male and female patients with an AMI.8
Sample and Setting

The study was conducted at 4 urban university
medical centers and 2 private hospitals in the United
States and 1 tertiary teaching hospital in Australia.
The convenience sample included 532 patients admitted to the coronary care unit who had a diagnosis of
AMI confirmed by elevated cardiac enzyme levels and
electrocardiographic changes compatible with an
AMI. Participants were in a stable medical condition
(eg, no pain, no life-threatening dysrhythmias or perfusion problems), were able to communicate coherently, and had no comorbid conditions such as sepsis,
stroke, or acute renal or liver failure. Study site facilities did not provide adjunctive therapy for smoking cessation at the time the data were collected, and tobacco
cessation was not the focus of the original study.
Procedure

Data were collected by cardiovascular nurses trained
in interviewing techniques and data abstraction from
medical records. Interviews were conducted within 72
hours of admission when patients were in stable condition and free of pain. Integrity of the interview data
was maintained across study sites by using a standardized protocol interview and data collection form. Clinical and demographic data were abstracted from the
medical record. A detailed description of the original
study protocol approved by the institutional review board
is provided elsewhere.8 The original data set was used
with no modification of the variables.
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Measures

Anxiety. Anxiety was evaluated by using the State
Anxiety Inventory (SAI) from the State Trait Anxiety
Inventory26 questionnaire and the Brief Symptoms
Inventory (BSI) 6-item anxiety subscale by Derogatis
and Melisaratos.27 Two instruments were used to measure each patient’s state anxiety to ensure that the
results accurately reflected state anxiety in this sample.
Both instruments, especially the SAI, have been widely
used individually in previous research to measure state
anxiety in patients with AMI, but no reports of both
instruments being used together have been published.
A person’s state anxiety is a measure of anxiety at the
time the instrument is completed, whereas the trait
anxiety is a measure of how the person generally feels.
Trait anxiety and state anxiety are highly correlated.26
The reliability and validity of the SAI have been
supported for healthy and ill populations.26 The SAI α
coefficients for internal consistency reliability range
from .86 to .95, and the SAI has established content,
concurrent, and construct validity.26 The SAI consists
of 20 statements that are rated on a 4-point gradient
scale from 1 (not at all) to 4 (very much). The 20 item
scores are summed with a total score that can range
from 20 (low anxiety) to 80 (high anxiety). In previous studies, normative values for persons 50 to 69
years old were 34.5 (SD 0.3) for men and 32.2 (SD
8.7) for women.26 The mean score for general medical
surgical patients was 42.4 (SD 13.8), and the mean
score for medical surgical patients with psychiatric
comorbid conditions was 47.7 (SD 3.2).26
The BSI is a 53-item self-report questionnaire
used to assess multiple dimensions of psychological
distress.27 The BSI was derived from the Symptom
Checklist-90-R to provide a psychometrically sound
shorter instrument. The BSI anxiety subscale and the
Symptom Checklist-90-R have a correlation of 0.95.27
The BSI anxiety subscale, consisting of 6 items rated
on a 5-point scale, was used for this study. Responses
on how much the subject is distressed by the signs and
symptoms of anxiety range from 0 (not at all) to 4
(extremely). Item scores are summed, and the mean is
calculated to provide a total score ranging from 0 to 4,
with higher scores indicating higher anxiety levels. Normative values for the BSI anxiety dimension are 0.35
(SD 0.45) for healthy persons, 1.7 (SD 1.15) for psychiatric inpatients, and 1.7 (SD 1.0) for psychiatric outpatients. The content, convergent, and construct validities
of the BSI have been established.28 Internal consistency
reliability analyses for the 2 anxiety measures for this
study were calculated. The Cronbach α values were .87
for the BSI and .61 for the SAI. The Pearson correlation
for the 2 scales for the study sample was 0.71 (P<.001).

http://ajcc.aacnjournals.org

Sociodemographic Characteristics. Sociodemographic data were collected by interview. The data
included patients’ sex, race, age, marital status, work
status, annual income, and education level.
Clinical Data. Detailed clinical information was collected on comorbid conditions (hypertension, diabetes,
previous AMI, smoking, angina, history of bypass graft
surgery, angioplasty, and diagnosis of coronary heart
disease without prior event) and complications (including ventricular fibrillation, ventricular tachycardia, congestive heart failure/pulmonary embolism, sudden
death, asystole, supraventricular tachycardia, atrioventricular block, sinus bradycardia and recurrent ischemia,
reinfarction, cardiogenic shock, and noncardiac death).
Smoking. Data on smoking were collected by asking the patient whether he or she currently smoked.
Data on the number of cigarettes per day or the years
of smoking were not collected.
Patterns of Use of Medications. Data on the use of
anxiolytic agents and β-blockers in the emergency
department and during hospitalization were extracted
from the medical records by nurses trained in cardiac
research. Medication use was coded as yes or no.
Peak Pain. Peak pain was assessed by asking
patients to rate the intensity of the pain they experienced during their initial event on a scale of 0 to 10,
with 0 being no pain and 10 being the most pain. This
simple rating scale is easily administered and understood and is applicable in the clinical setting.
Data Analysis

The data were first analyzed descriptively by using
means and SDs or frequency distributions, as appropriate. The Cronbach α was used to assess internal
consistency of scale items. Bivariate comparisons were
accomplished by using χ2 tests of association or independent samples t tests. Multiple linear regression was
used to determine whether smokers and nonsmokers
differed on anxiety after controlling for the demographic characteristics of age, sex, peak pain, and use
of β-blockers. Multiple logistic regression was used to
discern differences in use of β-blockers and anxiolytic
medications between smokers and nonsmokers, controlling for patients’ peak pain level, sex, age, and
anxiety. The Hosmer-Lemeshow goodness-of-fit test
was used to assess the fit of the logistic models to the
data. For each of the regression analyses, variance
inflation factors were estimated for each of the predictors, and levels of multicollinearity were assumed to
be acceptable because all variance inflation factors
were less than 4.29 All data analyses were performed
by using SPSS for Windows (version 12.0)30; P values
of .05 or less were deemed acceptable.
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Table 1 Demographic characteristics of smokers and nonsmokers included in the study*

Characteristic
Age, mean (SD), y
Education, mean
(SD), y

Total
sample
(N = 532)

Smokers
(n = 181)
(34%)

61.9 (13.5) 54.5 (12.7)
12.8 (3.1) 12.9 (2.83)

Nonsmokers
(n = 351)
(66%)
65.4 (12.3)†
12.8 (3.36)

Sex
Male
Female

354 (67)
177 (33)

128 (71)
53 (29)

226 (65)
124 (35)

Marital status
Married
Not married

369 (70)
161 (30)

118 (66)
61 (34)

251 (72)
100 (28)

Race
White
Nonwhite

462 (87)
67 (13)

150 (83)
30 (17)

312 (89)
37 (11)

Income level, $
≤20,000
20,001-59,999
≥60,000

171 (36)
235 (50)
68 (14)

47 (29)
93 (57)
24 (15)

124 (40)
142 (46)
44 (14)

*Values are No. (%) of patients unless otherwise indicated. Data
were not available for all characteristics for all groups. For example,
data on income level were available for only 310 of the 351 nonsmokers. All percentages are calculated on the basis of the number
of respondents for that characteristic. Percentages may not total
100 because of rounding.

95% CI 1.35 to 2.78; P < .001). However, when anxiety levels were compared between patients who previously had an AMI and patients who had not, no
significant differences were detected with either anxiety scale. Nonsmokers also tended to experience more
complications than smokers (mean number of events:
0.98 [SD 1.29] for nonsmokers vs 0.76 [SD 0.92] for
smokers; P = .05).
Smokers reported significantly higher levels of anxiety than nonsmokers when anxiety was measured by
using the SAI and the BSI anxiety subscale (Table 2).
The mean peak pain level was higher in smokers (7.4
[SD 2.78]) than in nonsmokers (6.8 [SD 2.67]; P = .01)
when evaluated on a scale of 0 to 10, with 10 representing the highest possible pain level. The anxiety scores
on both scales and the peak pain scores were significantly higher in women than in men. Female smokers
reported the highest anxiety and peak pain levels compared with male smokers and all nonsmokers.

Smokers received anxiolytic agents in
the emergency department and hospital
more often than nonsmokers did.

†P < .001.

Results
Table 1 shows the demographic characteristics of
the sample (N = 532), which comprised 181 smokers
(34%) and 351 nonsmokers (66%) recruited from multiple clinical sites. The mean number of days hospitalized
did not differ significantly (P = .37) between smokers
(5.7 [SD 4.34] days) and nonsmokers (6.0 [SD 4.55]
days). The sample was predominantly male, white, and
married, with a mean education level of 12.8 (SD 3.1)
years. The only significant difference (P < .001) between
the groups was in age: smokers (54.5 [SD 12.7] years)
were younger than nonsmokers (65.4 [SD 12.3] years).

Smokers reported higher levels of anxiety
than nonsmokers; female smokers
reported the highest anxiety levels.

One fourth of the sample had a history of a previous AMI. Nonsmokers were almost twice as likely as
smokers to report a previous AMI (odds ratio = 1.9,
620

Medication differences between smokers and nonsmokers were examined by using χ2 analyses (Table 3).
The administration of anxiolytic agents in the emergency department or on an as-needed basis did not
differ significantly between smokers and nonsmokers.
Both smokers and nonsmokers were more likely to
receive a β-blocker (46%) than an anxiolytic agent
(32%) in the emergency department. More than half
of smokers (53%) received a β-blocker in the emergency department compared with only 42% of nonsmokers (χ2 = 5.1, P = .02).
More than one third (37%) of men received an
anxiolytic agent in the emergency department, compared with less than a fourth (23%) of women (χ2 = 9.8,
P = .002). Administration of β-blockers in the emergency department did not differ significantly between
men and women among smokers or nonsmokers. When
male and female smokers were compared with respect
to medications administered in the emergency department, 42% of male smokers received an anxiolytic compared with 21% of female smokers (χ2 = 6.9, P = .008),
and male smokers (58%) were more likely than female
smokers (40%) to receive a β-blocker (χ2 = 4.4, P = .03).
After the emergency department, however, differences
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Table 2 Comparisons of scores for anxiety and peak pain levels by smoking status and sex of patient*
Total sample
(N = 532)

Measure
State anxiety

51.9 (14.8)

Smokers (n = 181)
Male

Total
54.4

(14.9)†

Nonsmokers (n = 351)

Female

52.7 (5.3) 58.2

(13.4)†

Total

Male

Female

50.6 (14.6) 49.2 (15.2) 53.1 (13.4)†

Brief Symptoms
Inventory anxiety

1.4 (1.17)

1.6 (1.18)†

1.4 (1.18)

2.0 (1.13)†

1.3 (1.15)

1.2 (1.10)

1.5(1.22)†

Peak pain

7.0 (2.55)

7.4 (2.78)†

7.1 (2.30)

8.1 (2.07)†

6.8 (2.67)

6.6 (2.53)

7.1 (2.88)†

*All values are mean (SD) of the scores on that measure.
†Significant difference (P < .05) between smokers and nonsmokers.
‡Significant difference (P < .05) between men and women.

Table 3 Chi-square comparisons of medications administered in smokers and nonsmokers*
Smokers

Nonsmokers

Total sample
(N = 532)

Total
(n = 181)

Male
(n = 128)

Female
(n = 53)

Total
(n = 351)

Male
(n = 226)

Female
(n = 124)

Anxiolytic agent in
emergency department

167 (32)

64 (36)

53 (42)

11 (21)

103 (30)

74 (34)

29 (24)

Anxiolytic agent as needed

246 (47)

92 (52)

66 (53)

26 (50)

154 (44)

101 (45)

53 (43)
53 (43)
108 (87)

Medication

β-blocker in emergency
department

236 (46)

β-blocker in hospital

449 (85)

92

72 (58)

20 (40)

144 (42)

91 (41)

108 (86)

48 (91)

293 (84)

185 (82)

(53)†

156 (87)

*All values are No. (%) of patients; percentages are based on the n for each variable, which in some cases is less than the total reported in the
column heading because of missing data.
†Significant difference (P < .05) between smokers and nonsmokers.

in use of β-blockers during hospitalization related to
smoking status or sex of the patient were not significant. Use of β-blockers is a universally standard clinical protocol for patients with AMI, and 85% of the
patients in this study received this medication.
Next, multiple regression analysis was used to
determine whether smokers and nonsmokers differed in
anxiety levels when we controlled for age, sex, peak
pain level, and use of β-blockers during hospitalization.
Two separate regression models were run with the total
state anxiety score after AMI as the dependent variable
for one of the models and the total scores of 6 BSI anxiety subscale items as the dependent variable for the
other model (Table 4). Smoking status was not significant in either model after we controlled for the patient’s
age, sex, peak pain level, and use of β-blockers. The
number of cases included in these models was less than
the total sample because data for some of the participants were missing on one or both anxiety measures.
Sociodemographic characteristics did not differ
between the subjects included in the regression models
and the total sample. Because the age and proportion of

http://ajcc.aacnjournals.org

smokers differed between men and women, sex-age and
smoke-sex interaction variables were included in the 2
regression models; these variables were not significant
and consequently were deleted in the final models.
Differences between smokers and nonsmokers
with respect to use of anxiolytic agents and β-blockers
in the emergency department and during hospitalization were examined by using logistic regression analysis (Table 5). Separate models were constructed with
the 4 patterns of medication use as dependent variables, smoking status as the predictor variable, and
state anxiety, BSI anxiety subscale, peak pain level,
sex, and age of the patient included as control variables. Even after these personal and demographic
characteristics were controlled for, smokers were more
likely than nonsmokers to receive an anxiolytic agent
in the emergency department and as needed in the
hospital (odds ratio=1.78, 95% CI 1.11 to 2.84, P=.01);
smokers also were more likely than nonsmokers to
receive a β-blocker in the emergency department
(odds ratio = 1.62, 95% CI 1.02 to 2.60, P = .04). Use
of β-blockers in the hospital did not differ significantly
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Table 4 Results of multiple regression analysis to compare anxiety levels between smokers and nonsmokers, with peak pain levels,
use of β-blockers, sex, and age of patients controlled for
Outcome variable

Adjusted R2

F

P

0.0069

6.9

<.001

State Trait Anxiety
Inventory (n = 398)

0.101

Brief Symptoms
Inventory (n = 401)

<.001

10.0

Standard β

P

Smoking status

0.060

.26

Peak pain

0.128

.01*

Female sex = 0

-0.159

.002*

β-blocker (hospital)

-0.061

.21

Age

-0.170

.002*

Covariates

Smoking status

0.035

.49

Peak chest pain

0.215

.001*

Female sex = 0

-0.149

.003*

β-blocker (hospital)

-0.017

.720

Age (y)

-0.176

.001*

* Significantly different between smokers and nonsmokers.

Table 5 Odds ratios and 95% CIs for logistic regression models to determine differences between smokers’ and nonsmokers’ use
of medications, with anxiety, peak pain level, age, and sex controlled for*
In emergency department

Variable

In hospital

Anxiolytic
(n = 390)

β-blocker
(n = 392)

Odds ratio 95% CI

Odds ratio 95% CI

Smoker

2.0†

Brief Symptoms
Inventory anxiety

0.9

State anxiety

1.0

1.2-3.4

1.6†

0.6-1.1

1.1

1.0-1.1

1.0

Anxiolytic as needed
(n = 394)

β-blocker
(n = 398)

Odds ratio

95% CI

Odds ratio

95% CI

1.0-2.6

1.8†

1.1-2.8

1.1

0.6-2.3

0.9-1.5

1.0

0.8-1.3

1.0

0.7-1.5

1.0-1.0

1.0

1.0-1.0

1.0

1.0-1.0
0.9-1.0

Age

1.0

1.0-1.0

1.0

1.0-1.0

1.0

1.0-1.0

1.0‡

Peak pain

0.8†

0.8-0.9

0.9†

0.8-1.0

0.9†

0.8-1.0

1.0

0.9-1.1

Sex

2.1‡

1.2-3.6

1.1

0.7-1.7

1.1

0.8-1.8

0.5†

0.3-1.0

*The sample size in the heading of each column is the number of cases with complete data on all variables in the regression and thus is the
effective sample size for that model.
†P < .05.
‡P < .01.

between smokers and nonsmokers. All medication models were examined for an interaction between sex of the
patients and smoking. These models are not reported
because the variance inflation factors were 9 or greater,
indicating unacceptable levels of multicollinearity.29

Discussion
In this study, we examined whether 2 important
universal clinical variables for patients hospitalized
because of AMI (the level of anxiety experienced and
the use of anxiolytics and β-blockers to reduce anxiety) differed significantly between smokers and nonsmokers. Medications are an important treatment for

622

AMI patients. When no contraindications are apparent,
β-blockers are a universal standardized treatment after
AMI because they reduce morbidity and mortality
rates.1 One effect of β-blockers is their ability to reduce
anxiety. Antianxiety medications are also frequently
given to AMI patients to calm the patients’ emotional
state.31 For this reason, studies measuring anxiety in
patients with AMI should examine the combined effects
of β-blockers and antianxiety agents.
The high anxiety scores of these AMI patients are
consistent with the findings in other studies.4-8 These
AMI patients’ mean SAI anxiety levels were higher
(51.9) than reported normative values for males and
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females of a similar age group (34 and 32).26 The bivariate analyses of this multicenter study show that smokers reported significantly higher anxiety levels than
nonsmokers reported when the 2 groups were asked
about their anxiety level within 72 hours after hospitalization for an AMI. The mean state anxiety level of
smokers was 54.4 compared with 50.6 for nonsmokers; female smokers reported the highest mean anxiety
scores (58.2).

Anxiety symptoms in smokers may have
been related to nicotine withdrawal.

However, regression models for the 2 anxiety measures indicated that after peak pain level, age, and sex
of the patient were controlled for, smokers and nonsmokers did not differ significantly on these outcomes.
Smoking status was not a significant variable in either
model. Conversely, when the use of a β-blocker or an
anxiolytic agent in the emergency department and as
needed during hospitalization was examined with logistic regression (Table 5), a different picture emerged.
Smokers were twice as likely to receive an anxiolytic
agent in the emergency department, more than 60%
more likely to receive a β-blocker in the emergency
department, and 80% more likely to receive an anxiolytic agent as needed during hospitalization when we
controlled for anxiety level, age, peak pain level, and
sex of the patient. Smokers may have had more signs
and symptoms of anxiety if they were experiencing
the onset of nicotine withdrawal during the admission
to the emergency department and throughout hospitalization. They may have more readily vocalized their
anxiousness to the clinicians and consequently received
more anxiolytic or β-blocker medications both in the
emergency department and in the hospital. Their higher
anxiety levels associated with an AMI event may be
explained by the psychophysiological stress perspective that smokers may respond to stressful situations
with greater autonomic arousal (increased heart rate and
blood pressure) than nonsmokers do. This theory is
plausible, because many smokers also have hypertension, and one theory of hypertension is that hypertensive
persons have increased autonomic arousal reactivity.
Another interesting finding in this study was that
patients with reported lower levels of peak pain were
more likely to receive an anxiolytic agent and a β-blocker
in the emergency department as well as an anxiolytic
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agent as needed during hospitalization when we controlled for anxiety levels, smoking status, age, and sex
of the patient. The patients’ recall of the peak pain intensity may have been altered by the use of the anxiolytic
agent or β-blocker as needed during hospitalization.
Men were more likely than women to receive an anxiolytic agent in the emergency department, and, conversely, women were more likely than men to receive
a β-blocker in the hospital when we controlled for the
same variables. With bivariate analysis, male smokers
were more likely than female smokers to receive both
an anxiolytic agent and a β-blocker in the emergency
department. Age was a significant predictor of use of
β-blockers during hospitalization.
Nonsmokers were about 10 years older than smokers, a difference that may explain why the nonsmokers
were more likely to have a history of previous AMI and
more complications than smokers. Unlike the findings
in studies in which smokers and nonsmokers were compared, education or income did not differ between
smokers and nonsmokers in this multisite study. Smokers usually have lower education and income levels than
nonsmokers do.3 Income is more likely to be site-specific for this sample and thus conveys less information
about true socioeconomic status, especially since one
site was outside the United States.

Males were more likely than females
to receive an anxiolytic agent in the
emergency department.

Limitations
These findings must be viewed with caution because
anxiety and pain data were collected retrospectively
by asking patients to recall their physical and emotional states after the event. Participants may have
been under the influence of medications (eg, β-blockers, antianxiety medications, analgesic agents) that
may have reduced their anxiety when they provided
their recollection of the acute event. Smokers may
have been experiencing nicotine withdrawal during
data collection because adjunctive treatment for nicotine cessation was not a standard of care at the time of
data collection.
Smoking data were not quantified, and the use of
other tobacco products was not elicited. A dose response
often occurs with smoking cessation; more addicted
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smokers, those who smoke more each day and have
more pack years, usually experience higher anxiety
levels when deprived of nicotine than do less addicted
smokers.32 Measuring true nicotine consumption is
difficult because the number and depth of inhalations
are variable among those who smoke the same number
of cigarettes per day. However, self-reports of smoking
status are both sensitive (87.5%) and specific (89.3%)
when compared with biochemical tests (eg, cotinine
assays of serum, saliva, or hair).33
Other studies suggest that because of decreasing
social acceptability and tolerance for secondhand smoke,
smokers often underreport tobacco use.34 Smokers with
comorbid anxiety, psychiatric, or alcohol use disorders
may experience increased anxiety when deprived of
nicotine. Also, some patients may have more marked
objective signs of anxiety (eg, increased heart rate and
blood pressure). Consequently, clinical staff may interpret these objective signs and administer medications
without validating the patient’s state of mind.

Clinical Implications
Despite the limitations of this secondary data
analysis, the findings of this initial comparison of anxiety levels between smokers and nonsmokers suggest
that all AMI patients, but especially smokers, should
be closely monitored for objective and subjective
signs of anxiety. Periodically, they should be asked
about their anxiety level and should be given antianxiety medications as appropriate.35,36 Kim et al8 and others37 report that women have higher anxiety levels than
men do, and the findings of this study suggest that
female smokers are a high-risk group for complications because this group reported the highest anxiety
levels but were less likely to receive antianxiety medications. During hospital admission and orientation,
AMI patients should be informed that it is important
for them to report feelings of anxiousness and that it is
appropriate to ask for antianxiety medication.
Additional studies are needed to examine further
the relationships between smoking status, anxiety levels, and medication use with diverse ethnic samples.
Smokers and nonsmokers from different ethnic groups
may report the experience of anxiety differently. Their
different experiences may affect clinical outcomes.
Anxiety levels should be examined with a group of
smokers who receive pharmacological cessation therapy during hospitalization. Studies employing a biochemical measure of nicotine addiction and both the
behavioral and physiological components of anxiety
may elucidate a clearer understanding of these relationships and consequent clinical outcomes.
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